Literature DB >> 6328010

Immunogenicity of herpes simplex virus glycoproteins gC and gB and their role in protective immunity.

J Glorioso, C H Schröder, G Kumel, M Szczesiul, M Levine.   

Abstract

The relative antigenicity of the individual herpes simplex virus type 1 (KOS) glycoproteins gC and gB was analyzed in BALB/c mice by using KOS mutants altered in their ability to present these antigens on cell surface membranes during infection. The mutants employed were as follows: syn LD70 , a non-temperature-sensitive mutant defective in the synthesis of cell surface membrane gC; tsF13 , a temperature-sensitive mutant defective in the processing of the precursor form of gB to the mature cell surface form at 39 degrees C; and ts606 , an immediate early temperature-sensitive mutant defective in the production of all early and late proteins including the glycoproteins. By comparing the relative susceptibility to immunolysis of mouse 3T3 cells infected at 39 degrees C with wild-type virus, presenting the full complement of the glycoprotein antigens, gC, gB, and gD, with target cells infected with mutants presenting only subsets of these antigens, we determined that a major portion of cytolytic antibody contained in hyperimmune anti-herpes simplex virus type 1 (KOS) mouse antiserum was directed against glycoproteins gC and gB. The relative immunogenicity of wild-type and mutant virus-infected cells also was compared in BALB/c mice. Immunogen lacking the mature form of gB induced a cytolytic antibody titer comparable to that of the wild-type virus, whereas that lacking the mature form of gC showed a 70% reduction in titer. The absence of the mature cell surface forms of gB and gC in immunogen preparations resulted in a 4- to 15-fold reduction in in virus neutralizing titer. Animals immunized with ts606 -infected cells (39 degrees C) induced relatively little virus-specific cytolytic and neutralizing antibody. Analysis of the glycoprotein specificities of these antisera by radioimmunoprecipitation showed that the antigens immunoprecipitated reflected the viral plasma membrane glycoprotein profiles of the immunogens. The absence of the mature forms of gC or gB in the immunizing preparation did not appreciably affect the immunoprecipitating antibody response to other antigens. Mice immunized with wild-type and mutant virus-infected cells were tested for their resistance to intracranial and intraperitoneal challenge with the highly virulent WAL strain of herpes simplex virus type 1. Despite the observed alterations in serum virus-specific antibody induced with the individual immunogens, all animals survived an intraperitoneal challenge of 10 50% lethal doses. However, differences in the survival of animals were obtained upon intracranial challenge.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6328010      PMCID: PMC255740     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Early damage of herpes-infected cells by antibody-dependent cellular cytotoxicity: relative roles of virus-specified cell-surface antigens and input virus.

Authors:  S L Shore; T L Cromeans; B Norrild
Journal:  J Immunol       Date:  1979-11       Impact factor: 5.422

2.  Herpes simplex virus glycoproteins: participation of individual herpes simplex virus type 1 glycoprotein antigens in immunocytolysis and their correlation with previously identified glycopolypeptides.

Authors:  B Norrild; S L Shore; A J Nahmias
Journal:  J Virol       Date:  1979-12       Impact factor: 5.103

3.  Postexposure serum prophylaxis of neonatal herpes simplex virus infection of mice.

Authors:  S Baron; M G Worthington; J Williams; J W Gaines
Journal:  Nature       Date:  1976-06-10       Impact factor: 49.962

4.  Passive immunization in experimental Herpesvirus hominis infection of newborn mice.

Authors:  F Luyet; D Samra; A Soneji; M I Marks
Journal:  Infect Immun       Date:  1975-12       Impact factor: 3.441

5.  Ocular infection with herpes simplex virus type 1: prevention of acute herpetic encephalitis by systemic administration of virus-specific antibody.

Authors:  W B Davis; J A Taylor; J E Oakes
Journal:  J Infect Dis       Date:  1979-10       Impact factor: 5.226

6.  Preparation and characterization of specific antisera to individual glycoprotein antigens comprising the major glycoprotein region of herpes simplex virus type 1.

Authors:  R Eberle; R J Courtney
Journal:  J Virol       Date:  1980-09       Impact factor: 5.103

7.  Efficacy of herpes simplex virus type 1 immunization in protecting against acute and latent infection by herpes simplex virus type 2 in mice.

Authors:  R R McKendall
Journal:  Infect Immun       Date:  1977-05       Impact factor: 3.441

8.  Antibody-mediated recovery from subcutaneous herpes simplex virus type 2 infection.

Authors:  J E Oakes; H Rosemond-Hornbeak
Journal:  Infect Immun       Date:  1978-08       Impact factor: 3.441

9.  Lymphocyte reactivity contributes to protection conferred by specific antibody passively transferred to herpes simplex virus-infected mice.

Authors:  J E Oakes; W B Davis; J A Taylor; W A Weppner
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

10.  Type-common and type-specific monoclonal antibody to herpes simplex virus type 1.

Authors:  L Pereira; T Klassen; J R Baringer
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

View more
  26 in total

1.  Identification of an immunodominant cytotoxic T-lymphocyte recognition site in glycoprotein B of herpes simplex virus by using recombinant adenovirus vectors and synthetic peptides.

Authors:  T Hanke; F L Graham; K L Rosenthal; D C Johnson
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

2.  Passive immune protection by herpes simplex virus-specific monoclonal antibodies and monoclonal antibody-resistant mutants altered in pathogenicity.

Authors:  G Kümel; H C Kaerner; M Levine; C H Schröder; J C Glorioso
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

3.  Antigenic variation (mar mutations) in herpes simplex virus glycoprotein B can induce temperature-dependent alterations in gB processing and virus production.

Authors:  S D Marlin; S L Highlander; T C Holland; M Levine; J C Glorioso
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

4.  Epstein-Barr virus glycoprotein homologous to herpes simplex virus gB.

Authors:  M Gong; T Ooka; T Matsuo; E Kieff
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

5.  Amino-terminal sequence, synthesis, and membrane insertion of glycoprotein B of herpes simplex virus type 1.

Authors:  L Claesson-Welsh; P G Spear
Journal:  J Virol       Date:  1987-01       Impact factor: 5.103

6.  Use of epitope mapping to identify a PCR template for protein amplification and detection by enzyme-linked immunosorbent assay of bovine herpesvirus type 1 glycoprotein D.

Authors:  Tomy Joseph; Japhet Lyaku; Robert A Fredrickson; Arnost Cepica; Frederick S B Kibenge
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

7.  Identification and nucleotide sequence of the glycoprotein gB gene of equine herpesvirus 4.

Authors:  M P Riggio; A A Cullinane; D E Onions
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

8.  Epitopes of herpes simplex virus type 1 glycoprotein gC are clustered in two distinct antigenic sites.

Authors:  S D Marlin; T C Holland; M Levine; J C Glorioso
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

9.  Necrotizing chorioretinitis in mice inoculated with herpes simplex virus type 1 with or without glycoprotein C: anterior chamber-associated immune deviation does not persist.

Authors:  Y Liu; H Minagawa; Y Toh; Y Sakai; T Ishibashi; H Inomata; R Mori
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

10.  A comparison of T cell responses to glycoprotein B (gB-1) of herpes simplex virus type 1 and its non-glycosylated precursor protein, pgB-1.

Authors:  C A O'Donnell; W L Chan
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.